Antibody-mediated modulation of major histocompatibility complex (MHC) molecules, or
MHC class I-like molecules, could constitute an effective immunotherapeutic approach. We …

Recombinant protein-based biotherapeutics drugs have transformed clinical pipelines of the
biopharmaceutical industry since the launch of recombinant insulin nearly four decades ago …

As a breakthrough immunotherapy, T cell bispecific antibodies (T-BsAbs) are a promising
antibody therapy for various kinds of cancer. In general, T-BsAbs have dual-binding …

Bispecific T-cell engagers (BiTEs) redirect endogenous T-cell populations to cells
expressing tumour-associated antigens to induce tumour cell killing. This inherently relies …

Neural cell adhesion molecule L1 (L1CAM) is a cell-surface glycoprotein involved in cancer
occurrence and migration. Up to today, L1CAM-targeted therapy appeared limited efficacy in …

Whereas the treatment of MM was dependent solely on alkylating agents and corticosteroids
during the prior three decades, the landscape of therapeutic measures to treat the disease …

Background Bispecific T cell engagers represent the majority of bispecific antibodies
(BsAbs) entering the clinic to treat metastatic cancer. The ability to apply these agents safely …

Multiple myeloma (MM) patients eventually develop multi-drug-resistant disease with poor
survival. Hence, the development of novel treatment strategies is of great importance …

The use of T-cell engagers (TCEs) to treat solid tumors is challenging, and several have
been limited by narrow therapeutic windows due to substantial on-target, off-tumor toxicities …

ABSTRACT T-cell bispecific antibodies (T-BsAbs) are a new class of cancer immunotherapy
drugs that can simultaneously bind to tumor-associated antigens on target cells and to the …